Rotavirus vaccine - Rhein BiotechAlternative Names: Rotavax
Latest Information Update: 12 Oct 2006
At a glance
- Originator Rhein Biotech
- Class Rotavirus vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rotavirus infections
Most Recent Events
- 12 Oct 2006 Discontinued - Preclinical for Rotavirus infections in Germany (unspecified route)
- 31 Oct 2002 Rhein Biotech has been acquired by Berna Biotech
- 16 Jul 2001 New profile